The efficacy and safety of premarin and estrogel for thawed blastocyst transfer in patients with infertility - A prospective randomized controlled trial

The efficacy and safety of premarin and estrogel for thawed blastocyst transfer in patients with infertility - A prospective randomized controlled trial - The efficacy and safety of premarin and estrogel for thawed blastocyst transfer in patients with infertility - A prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015488

Enrollment

1000

Registered

2014-10-21

Start date

2014-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Oral administration of premarin (0.632mg per tablet, twice a day). Continuous administration until pregnancy determination date from the second day of menstruation. Estrogel (2.16mg per day in Estro

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Infertile patients. Provided written informed consent.

Exclusion criteria

Exclusion criteria: Patients that fall into contraindication to estrogel and premarin.

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate	—

Secondary

Measure	Time frame
Ongoing pregnancy rate	—

Countries

Japan

Contacts

Public ContactSagiri Taguchi

Oak Clinic Group IVF Center

taguchi_s@oakclinic-group.com06-4398-1000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026